Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024
Carisma Therapeutics (NASDAQ: CARM) presented promising preclinical data on engineered macrophages for treating liver fibrosis at AASLD The Liver Meeting® 2024. The research shows that macrophages can be genetically engineered to target specific pathways in liver disease using factors like TIM4, relaxin, and IL10. A single dose of TIM4-expressing macrophages, alone or with relaxin, significantly reduced liver fibrosis in the CDAHFD MASH model. The engineered cells were well-tolerated and outperformed non-engineered cells. The company plans to nominate a development candidate for its liver fibrosis program in Q1 2025.
Carisma Therapeutics (NASDAQ: CARM) ha presentato dati preclinici promettenti sui macrofagi ingegnerizzati per il trattamento della fibrosi epatica durante l'AASLD The Liver Meeting® 2024. La ricerca dimostra che i macrofagi possono essere geneticamente modificati per mirare a specifici percorsi nella malattia epatica utilizzando fattori come TIM4, relaxina e IL10. Una singola dose di macrofagi che esprimono TIM4, da soli o con relaxina, ha ridotto significativamente la fibrosi epatica nel modello CDAHFD MASH. Le cellule ingegnerizzate sono state ben tollerate e hanno superato le cellule non ingegnerizzate. L'azienda prevede di nominare un candidato per lo sviluppo del suo programma sulla fibrosi epatica nel primo trimestre del 2025.
Carisma Therapeutics (NASDAQ: CARM) presentó datos preclínicos prometedores sobre macrófagos ingenierizados para tratar la fibrosis hepática en la AASLD The Liver Meeting® 2024. La investigación muestra que los macrófagos pueden ser modificados genéticamente para dirigirse a vías específicas en la enfermedad del hígado usando factores como TIM4, relaxina e IL10. Una sola dosis de macrófagos que expresan TIM4, solos o con relaxina, redujo significativamente la fibrosis hepática en el modelo CDAHFD MASH. Las células ingenierizadas fueron bien toleradas y superaron a las células no ingenierizadas. La empresa planea nominar a un candidato para el desarrollo de su programa de fibrosis hepática en el primer trimestre de 2025.
Carisma Therapeutics (NASDAQ: CARM)는 AASLD The Liver Meeting® 2024에서 간 섬유증 치료를 위한 엔지니어링 대식세포에 대한 유망한 preclinical 데이터를 발표했습니다. 연구에 따르면, 대식세포는 TIM4, 이완인, IL10과 같은 인자를 사용하여 간 질환의 특정 경로를 타겟팅하기 위해 유전적으로 조작될 수 있습니다. TIM4를 발현하는 대식세포의 단일 투여는 이완인과 함께 사용되든 단독으로 사용되든 CDAHFD MASH 모델에서 간 섬유증을 유의미하게 감소시켰습니다. 이 엔지니어링 셀은 잘 견디어냈으며 비엔지니어링 셀보다 성능이 뛰어났습니다. 회사는 2025년 1분기 내에 간 섬유증 프로그램을 위한 개발 후보를 지명할 계획입니다.
Carisma Therapeutics (NASDAQ: CARM) a présenté des données précliniques prometteuses sur des macrophages ingénierés pour le traitement de la fibrose hépatique lors de l'AASLD The Liver Meeting® 2024. La recherche montre que les macrophages peuvent être modifiés génétiquement pour cibler des voies spécifiques dans la maladie du foie en utilisant des facteurs tels que TIM4, relaxine et IL10. Une seule dose de macrophages exprimant TIM4, seule ou avec de la relaxine, a significativement réduit la fibrose hépatique dans le modèle CDAHFD MASH. Les cellules ingénierées ont été bien tolérées et ont surpassé les cellules non-ingenierées. L'entreprise prévoit de désigner un candidat pour le développement de son programme de fibrose hépatique au premier trimestre 2025.
Carisma Therapeutics (NASDAQ: CARM) präsentierte vielversprechende präklinische Daten zu ingenieurierten Makrophagen zur Behandlung von Leberfibrose auf dem AASLD The Liver Meeting® 2024. Die Forschung zeigt, dass Makrophagen genetisch so verändert werden können, dass sie gezielt auf spezifische Signalwege bei Lebererkrankungen abzielen, unter Verwendung von Faktoren wie TIM4, Relaxin und IL10. Eine einzelne Dosis von TIM4-exprimierenden Makrophagen, allein oder in Kombination mit Relaxin, reduzierte die Leberfibrose signifikant im CDAHFD MASH-Modell. Die ingenieurierten Zellen wurden gut vertragen und übertrafen nicht-ingenieierte Zellen. Das Unternehmen plant, im ersten Quartal 2025 einen Entwicklungs-Kandidaten für sein Leberfibrose-Programm zu nominieren.
- Preclinical data showed significant reduction in liver fibrosis with single dose treatment
- Engineered macrophages demonstrated superior performance compared to non-engineered cells
- Treatment was well-tolerated in preclinical models
- Clear development timeline with candidate nomination planned for Q1 2025
- Product still in early preclinical stage
- No human trial data available yet
- Significant time and investment needed before potential commercialization
Insights
The preclinical data demonstrates significant therapeutic potential in treating liver fibrosis through engineered macrophages. The key breakthrough lies in the multi-modal approach: TIM4 expression for improved efferocytosis, relaxin for hepatic stellate cell inhibition and IL10 for inflammation reduction. The single-dose efficacy in the CDAHFD MASH model is particularly noteworthy, suggesting strong therapeutic potential.
The development addresses a substantial market opportunity in liver disease treatment, particularly for MASH (formerly known as NASH), which affects an estimated
While promising, investors should note that a development candidate nomination isn't expected until Q1 2025, indicating a lengthy timeline to potential commercialization. Clinical trials will be important to validate these preclinical results in human subjects.
New preclinical results support the anti-fibrotic potential of engineered macrophages in multiple fibrosis models
Engineered TIM4-expressing macrophages correct defective efferocytosis in MASH, demonstrating potent anti-fibrotic activity
Liver fibrosis is a central late-stage pathway in multiple liver diseases, including MASH, acute liver injury, primary sclerosing cholangitis, primary biliary cholangitis, and others. Treatment options remain limited for advanced liver disease patients. Liver disease is characterized by defective efferocytosis (an anti-inflammatory process by which macrophages clear dead hepatocytes), activation of hepatic stellate cells which leads to collagen accumulation, and chronic inflammation.
New preclinical results demonstrate that macrophages can be genetically engineered to target specific key pathways underlying liver disease with factors including TIM4 (restores efferocytosis), relaxin (inhibits hepatic stellate cell activation), and IL10 (reduces inflammation). Notably, a single dose of macrophages expressing TIM4, alone or together with relaxin, significantly reduced liver fibrosis and hepatic stellate cell activation in the translationally relevant choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) MASH model. The engineered macrophages were well tolerated and outperformed non-engineered cells in all models.
"We are pleased to present compelling preclinical data supporting the therapeutic potential of our engineered macrophages to address a critical unmet need in liver fibrosis, which is found in advanced stages of MASH," said Michael Klichinsky, PharmD, PhD, Co-founder and Chief Scientific Officer of Carisma. "These data underscore the efficacy of our engineered macrophages as a differentiated, off-the-shelf approach for treating advanced liver fibrosis. Based on these promising findings, we are committed to advancing our liver fibrosis program."
Carisma expects to nominate a development candidate for its liver fibrosis program in the first quarter of 2025.
The poster presented at AASLD 2024 is now available online in the "Publications" section of Carisma's website at https://carismatx.com/technology/publications/
About Carisma Therapeutics
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and clinical development activities for Carisma's product candidates, the potential safety, efficacy, benefits and addressable market for Carisma's product candidates, and clinical trial results for Carisma's product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "continue," "will," "schedule," and "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on the Company's current expectations and projections about future events and various assumptions. Although Carisma believes that the expectations reflected in such forward-looking statements are reasonable, Carisma cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Carisma's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Carisma's ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, clinical trial sites and our ability to enroll eligible patients, supply chain and manufacturing facilities, Carisma's ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, Carisma's ability to fund development activities and achieve development goals, Carisma's ability to protect intellectual property, and other risks and uncertainties described under the heading "Risk Factors" in Carisma's Annual Report on Form 10-K for the year ended December 31, 2023, its Quarterly Reports on Form 10-Q and other documents that Carisma files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Carisma undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof, except as may be required by law.
Investors:
Shveta Dighe
Head of Investor Relations
investors@carismatx.com
Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-presents-promising-new-preclinical-data-on-engineered-macrophages-for-the-treatment-of-liver-fibrosis-at-aasld-the-liver-meeting-2024-302307382.html
SOURCE Carisma Therapeutics Inc.
FAQ
What were the key findings of Carisma Therapeutics (CARM) liver fibrosis treatment study?
When will Carisma Therapeutics (CARM) nominate a development candidate for liver fibrosis?
What technology is Carisma Therapeutics (CARM) using to treat liver fibrosis?
